Janux Therapeutics, Inc.
Janux Therapeutics, Inc. (JANX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
janx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Janux Therapeutics, Inc. (JANX) measures how much investors pay for each dollar of the company's trailing earnings. JANX's current PE ratio of N/A is calculated by dividing its stock price of $13.61 by its TTM earnings per share of -$1.83.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Janux Therapeutics, Inc.You JANX | $830M | N/A | — | -$1.83 |
 AbCellera Biologics Inc. ABCL | $1.6B | N/A | — | -$0.49 |
 Biohaven Ltd. BHVN | $1.2B | N/A | — | -$6.86 |
 Celldex Therapeutics, Inc. CLDX | $1.9B | N/A | — | -$3.89 |
 Harmony Biosciences Holdings, Inc. HRMY | $1.9B | 13.56x | — | $2.76 |
 Immunome, Inc. IMNM | $1.8B | N/A | — | -$2.43 |
 Maze Therapeutics, Inc. MAZE | $1.3B | N/A | — | -$3.05 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.83 | — | |
2024-12-31 FY2024 | — | $-1.28 | — | |
2023-12-31 FY2023 | — | $-1.32 | — | |
2022-12-31 FY2022 | — | $-1.52 | — | |
2021-12-31 FY2021 | — | $-0.79 | — | |
2020-12-31 FY2020 | — | $-0.16 | — | |
2019-12-31 FY2019 | — | $-0.10 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Janux Therapeutics, Inc. (JANX) measures how much investors pay for each dollar of the company's trailing earnings. JANX's current PE ratio of N/A is calculated by dividing its stock price of $13.61 by its TTM earnings per share of -$1.83.
Frequently asked questions
JANX pe ratio · 6 questionsJANX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $13.61 and TTM EPS of -$1.83. Data sourced from Financial Modeling Prep via JANX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Janux Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08